Viking Therapeutics (NASDAQ: VKTX) reported Q1 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17).

At March 31, 2017, Viking held cash, cash equivalents and investments totaling $12.3 million. As of April 30, 2017, Viking had 23,925,425 shares of common stock outstanding.

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.